ExCellThera Inc., a clinical stage biotechnology company focused on bioengineering solutions to expand stem and immune cells for therapeutic use, has entered into a manufacturing and collaboration agreement with Comprehensive Cell Solutions (CCS), a division of New York Blood Center (NYBC) for the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001. ExCellThera will have access to NYBC’s cGMP clean room manufacturing facilities in New York for the production of ECT-0...